menu
    • menu
    [{"orgOrder":0,"company":"Apollomics Inc","sponsor":"LaunXP Biomedical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Agreement","leadProduct":"Vebreltinib","moa":"||c-MET","graph1":"Oncology","graph2":"Phase II","graph3":"Apollomics Inc","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"Oral Tablet","sponsorNew":"Apollomics Inc \/ LaunXP Biomedical","highestDevelopmentStatusID":"8","companyTruncated":"Apollomics Inc \/ LaunXP Biomedical"},{"orgOrder":0,"company":"Apollomics Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vebreltinib","moa":"c-Met receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Apollomics Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Apollomics Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apollomics Inc \/ Inapplicable"},{"orgOrder":0,"company":"Apollomics Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vebreltinib","moa":"c-Met receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Apollomics Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Apollomics Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apollomics Inc \/ Inapplicable"},{"orgOrder":0,"company":"Apollomics Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vebreltinib","moa":"c-Met receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Apollomics Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Apollomics Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apollomics Inc \/ Inapplicable"},{"orgOrder":0,"company":"Apollomics Inc","sponsor":"Canaccord Genuity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Vebreltinib","moa":"c-Met receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Apollomics Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Apollomics Inc \/ Canaccord Genuity","highestDevelopmentStatusID":"8","companyTruncated":"Apollomics Inc \/ Canaccord Genuity"},{"orgOrder":0,"company":"Beijing Avistone Pharmaceuticals Biotechnology","sponsor":"SDIC CS Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Series B Financing","leadProduct":"Vebreltinib","moa":"c-Met receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Beijing Avistone Pharmaceuticals Biotechnology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Beijing Avistone Pharmaceuticals Biotechnology \/ SDIC CS Capital","highestDevelopmentStatusID":"15","companyTruncated":"Beijing Avistone Pharmaceuticals Biotechnology \/ SDIC CS Capital"},{"orgOrder":0,"company":"Apollomics Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vebreltinib","moa":"c-Met receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Apollomics Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Apollomics Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Apollomics Inc \/ Inapplicable"},{"orgOrder":0,"company":"Predicine","sponsor":"Apollomics Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Vebreltinib","moa":"c-Met receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Predicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Predicine \/ Apollomics Inc","highestDevelopmentStatusID":"8","companyTruncated":"Predicine \/ Apollomics Inc"},{"orgOrder":0,"company":"Apollomics Inc","sponsor":"Maxpro Capital Acquisition Corp.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Vebreltinib","moa":"c-Met receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Apollomics Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Apollomics Inc \/ Maxpro Capital Acquisition Corp.","highestDevelopmentStatusID":"7","companyTruncated":"Apollomics Inc \/ Maxpro Capital Acquisition Corp."},{"orgOrder":0,"company":"Apollomics Inc","sponsor":"Ping An Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series C Financing","leadProduct":"Vebreltinib","moa":"c-Met receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Apollomics Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Apollomics Inc \/ Ping An Capital","highestDevelopmentStatusID":"7","companyTruncated":"Apollomics Inc \/ Ping An Capital"},{"orgOrder":0,"company":"Beijing Avistone Pharmaceuticals Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vebreltinib","moa":"c-Met receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Beijing Avistone Pharmaceuticals Biotechnology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Beijing Avistone Pharmaceuticals Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Beijing Avistone Pharmaceuticals Biotechnology \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Vebreltinib

    Menu

    Vebreltinib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Apollomics Inc

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Apollomics Inc

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vebreltinib,Osimertinib Mesylate

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : LaunXP Biomedical

                            Deal Size : $60.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib

                            Details : under the agreement, LaunXP receives exclusive development and commercialization rights for APL-101 (vebreltinib) in combination with an EGFR inhibitor for the treatment of non-small cell lung cancer.

                            Product Name : APL-101

                            Product Type : Other Small Molecule

                            Upfront Cash : $10.0 million

                            March 31, 2025

                            Lead Product(s) : Vebreltinib,Osimertinib Mesylate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : LaunXP Biomedical

                            Deal Size : $60.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Apollomics Inc

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Apollomics Inc

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vebreltinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Apollomics Announces Positive Data for Vebreltinib in MET Fusion Tumors in Phase 2

                            Details : APL-101 (vebreltinib) is a small-molecule inhibitor that targets MET tyrosine kinase activity. It is being developed for the treatment of MET Exon 14 skip non-small cell lung cancer.

                            Product Name : APL-101

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 13, 2024

                            Lead Product(s) : Vebreltinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Apollomics Inc

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Apollomics Inc

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vebreltinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Canaccord Genuity

                            Deal Size : $6.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Apollomics Announces Private Placement Financing and Addition to Board of Directors

                            Details : Apollomics plans to use proceeds to fund pipeline programs including APL-101, a selective c-Met inhibitor, for treating non-small cell lung cancer and tumors with c-Met alterations.

                            Product Name : APL-101

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            August 05, 2024

                            Lead Product(s) : Vebreltinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Canaccord Genuity

                            Deal Size : $6.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Predicine

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Predicine

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vebreltinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Apollomics Inc

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Predicine Collaborates with Apollomics for Lung Cancer Companion Diagnostic

                            Details : The collaboration seeks to develop PredicineCARE, a blood cfDNA NGS assay to identify NSCLC patients who may benefit from therapy with APL-101 (vebreltinib), a small molecule c-Met inhibitor.

                            Product Name : APL-101

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            May 04, 2024

                            Lead Product(s) : Vebreltinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Apollomics Inc

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Beijing Avistone Pharmaceuticals Biotechnology

                            China arrow
                            AACR Annual meeting
                            Not Confirmed

                            Beijing Avistone Pharmaceuticals Biotechnology

                            China arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vebreltinib

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Avistone Approves Vebreltinib as First MET-TKI Treatment for Rare Glioma Subtype in China

                            Details : APL-101 (vebreltinib) is a highly specific cMet inhibitor which is indicated for the treatment of sGBM/IDH mutant glioblastoma with the ZM fusion gene.

                            Product Name : PLB1001

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 25, 2024

                            Lead Product(s) : Vebreltinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Beijing Avistone Pharmaceuticals Biotechnology

                            China arrow
                            AACR Annual meeting
                            Not Confirmed

                            Beijing Avistone Pharmaceuticals Biotechnology

                            China arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vebreltinib

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : SDIC CS Capital

                            Deal Size : $140.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Avistone Biotechnology Announces Closing of Series B Financing

                            Details : The net proceeds will be used to support clinical research and development of the Avistone pipeline, including PLB1001 (vebreltinib), a small-molecule inhibitor targeting MET tyrosine kinase activity.

                            Product Name : PLB1001

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            April 01, 2024

                            Lead Product(s) : Vebreltinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : SDIC CS Capital

                            Deal Size : $140.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Apollomics Inc

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Apollomics Inc

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vebreltinib

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung Cancer

                            Details : APL-101 (vebreltinib) is a small-molecule inhibitor that targets MET tyrosine kinase activity. It is being developed for the treatment of MET Exon 14 skip non-small cell lung cancer.

                            Product Name : APL-101

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 16, 2023

                            Lead Product(s) : Vebreltinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Apollomics Inc

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Apollomics Inc

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vebreltinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Apollomics Announces Two New Cohorts in Global Phase 2 SPARTA Study of Vebreltinib in Non-Small Cell Lung Canc...

                            Details : APL-101 (vebreltinib) is a highly specific cMet inhibitor which is under phase 2 clinical development in non-small cell lung cancer and other solid tumors with MET dysregulations.

                            Product Name : APL-101

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 31, 2023

                            Lead Product(s) : Vebreltinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Apollomics Inc

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Apollomics Inc

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vebreltinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Maxpro Capital Acquisition Corp.

                            Deal Size : $23.6 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Apollomics, a Company Developing Novel Oncology Therapies to Address Difficult-to-Treat Cancers, Announces Clo...

                            Details : Apollomics will use the financing to advance APL-101 (vebreltinib), a highly specific cMet inhibitor, in non-small cell lung cancer and other solid tumors with cMet dysregulation.

                            Product Name : APL-101

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            March 30, 2023

                            Lead Product(s) : Vebreltinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Maxpro Capital Acquisition Corp.

                            Deal Size : $23.6 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Apollomics Inc

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Apollomics Inc

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vebreltinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Ping An Capital

                            Deal Size : $124.0 million

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            Apollomics, Inc. Closes $124 Million Series C Financing

                            Details : Proceeds from the Series C financing will support the development of the Apollomics pipeline with a focus on the Company’s lead programs: APL-101 and APL-106.

                            Product Name : APL-101

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            June 11, 2020

                            Lead Product(s) : Vebreltinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Ping An Capital

                            Deal Size : $124.0 million

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth